Scientific Founders

Claude Perreault, M.D., F.C.A.H.S.

Dr. Claude Perreault is Principal Investigator of the Immunobiology Research Unit of the Institute for Research in Immunology and Cancer and a Professor, Department of Medicine, Université de Montréal.  Dr. Perrault devised with Dr. Pierre Thibault a unique proteogenomic high throughput discovery platform which permitted the identification of MiHAs.   His work has led to major advances in our understanding of graft versus host disease, in the treatment of leukemia and in the development of a cancer vaccine. Dr. Perreault has been involved in a number of large scale grants over the years including a Pfizer-FRSQ grant and as team leader in a previous Genome Québec/Canada Grant (Functional Genomics, Pharmacogenomics and Proteomics of the Immune Response in Health and Immune Related Disorders). Dr. Perreault is the Executive Chairman and Lead principal investigator of the Genome Canada Personalized Cancer ImmunoTherapy Program (www.pcitp.org); He also founded Compatigène inc, a biotech company.

Denis-Claude Roy, M.D., FRCPC

Dr. Denis-Claude Roy is currently Director of the Hôpital Maisonneuve-Rosemont Research Center and Medical Director of HMR’s Center of Excellence in Cell Therapy. He is also Director of the Clinical Applications Arm of the Canadian Stem Cell Network.  Previously he was a board member of the Canadian Blood and Marrow Transplant Group Hehas also been the leading academic partner for the development, translation and clinical evaluation of many new blood cancer treatments from the biopharma industry and has been collaborating with ImmunoGen (Boston, USA) and Kiadis Pharma (www.kiadis.com) for many years. Dr. Roy significantly contributed to the development of Kiadis’ blood cancer products ATIR™, Reviroc™ and Rhitol™ and is the principal investigator for the GLIDE clinical trial.

Jean-Sébastien Delisle, M.D., FRCPC, Ph.D.

Dr. Jean-Sébastien Delisle is currently Associate Professor, Department of Medicine, Université de Montréal and is a hematologist-scientist at Hôpital Maisonneuve-Rosemont (HMR). He holds an MD degree from McGill University and a Ph.D. from the University of Montreal. Dr. Delisle established his research group at HMR in late 2010 and has since developed a research program in basic and translational T-cell biology. He has notably led the “bench to bedside” translation of cell therapy approaches to treat Epstein-Barr virus lymphomas and to target hematopoietic-restricted MiHA. His laboratory is working on the differentiation and expansion of human T cells in vitro in order to support early phase clinical trials. To this end he has adapted validated culture systems and is currently developing several strategies in order to both increase the therapeutic potency of ex-vivo expanded T cells and study basic aspects of T-cell biology.

Pierre Thibault, Ph.D.

Dr. Pierre Thibault is the Principal Investigator of the Proteomics and Bioanalytical Mass Spectrometry research unit of the Institute for Research in Immunology and Cancer and a professor of the Department of Chemistry at Université de Montréal. Dr. Thibault devised with Dr. Perreault a unique proteogenomic high throughput MiHA discovery platform which permitted the identification of MiHA Dr. Thibault brings his combined expertise in bioanalytical mass spectrometry and protein chemistry to the development and implementation of new technologies in proteomics and cell biology. In multidisciplinary research, these tools provide a deeper understanding of molecular mechanisms and post-translational modifications, which regulate the function and translocation of proteins involved in immunity and signaling in cancer cells. In addition to his academic pedigree, Dr. Thibault was part of the management team of Caprion Proteomics inc.